antitumor activity

Related by string. Antitumor Activity * Anti Tumor . Antitumor : demonstrated antitumor activity . antitumor . antitumor effects . antitumor effect . antitumor efficacy / ACTIVITY . activ ity . Activity : contracting activity N# . DETECTS UNUSUAL ACTIVITY IN . Detects Unusual Activity . Physical Activity . gravitated toward Paranormal Activity * potent antitumor activity *

Related by context. All words. (Click for frequent words.) 75 antiviral activity 75 anti leukemic 73 cytotoxicity 71 xenograft models 70 antitumor effects 70 anticancer activity 70 axitinib 70 HGS ETR1 69 antitumor efficacy 69 ENMD # 69 antiviral efficacy 68 antitumor effect 68 tolerability profile 68 biodistribution 68 potent antitumor activity 68 ganetespib 68 PXD# 68 Carfilzomib 68 Azedra 68 PRT# 67 oral bioavailability 67 OXi# 67 antitumor 67 GRN#L 67 pertuzumab 67 pharmacokinetic profile 67 milatuzumab 67 HGS ETR2 67 bortezomib 67 fosbretabulin 67 ON #.Na 67 tolerability 67 enzastaurin 67 IMC A# 67 pharmacodynamic PD 66 antitumour activity 66 seliciclib 66 preclinically 66 orally bioavailable 66 VEGFR2 66 gemcitabine Gemzar 66 obatoclax 66 mapatumumab 66 induces apoptosis 66 heavily pretreated patients 66 favorable tolerability 66 vivo efficacy 66 Preclinical studies 66 adecatumumab 66 pharmacokinetic profiles 66 overlapping toxicities 66 HGS# 66 antiangiogenic activity 66 favorable pharmacokinetic profile 66 imetelstat 66 pomalidomide 66 INCB# [001] 66 CA4P 66 demonstrated antitumor activity 66 tumor regression 66 inhibitory effects 66 pharmacodynamic properties 66 teriflunomide 66 Symadex 66 vidofludimus 65 depsipeptide 65 cytotoxic 65 dose limiting toxicities 65 PSMA ADC 65 GLYX 65 CLORETAZINE TM VNP#M 65 angiogenesis inhibitor 65 neuroprotective properties 65 Bezielle 65 EGFr 65 erlotinib Tarceva ® 65 Imprime PGG 65 IMGN# 65 vitro cytotoxicity 65 OMP #M# 65 combinability 65 decitabine 65 systemic absorption 65 pharmacodynamic profile 65 HER2 positive metastatic breast 65 nab paclitaxel 65 Traficet EN 65 MGCD# [001] 65 pharmacokinetic properties 65 elacytarabine 65 APOPTONE 65 pharmacodynamic 65 HuMax EGFr 65 mouse xenograft models 65 Aplidin 65 entinostat 64 CCX# 64 EpCAM 64 heavily pretreated 64 systemically administered 64 pro apoptotic 64 GMX# 64 inhibitory activity 64 IFN α 64 selective inhibition 64 ENMD 64 relapsed refractory 64 preclinical models 64 huN# DM1 64 erlotinib 64 BRAF inhibitor 64 davunetide intranasal AL 64 Tarceva TM 64 sorafenib Nexavar 64 pharmacodynamic effects 64 docetaxel chemotherapy 64 Bortezomib 64 Aurora kinase 64 preclinical efficacy 64 SCH # 64 CIMZIA ™ 64 Enzastaurin 64 Tyrima 64 oral prodrug 64 azacitidine 64 complete remissions 64 erythropoietic 64 pan HDAC inhibitor 64 efficacy 64 tolerated dose MTD 64 Apoptone 64 nephrotoxicity 64 XL# [003] 64 BAY #-# 64 mertansine 64 chemotherapeutic agents 64 CYC# 64 limiting toxicity 64 plasma kallikrein inhibitor 64 gemcitabine carboplatin 64 alvespimycin 64 safety tolerability pharmacokinetic 63 liposomal formulation 63 PEG SN# 63 carboplatin paclitaxel 63 cytoprotective 63 investigational humanized monoclonal antibody 63 AP# [003] 63 metastatic renal cell carcinoma 63 #ME# 63 viral kinetics 63 effector function 63 vivo potency 63 pegylated liposomal doxorubicin 63 antiproliferative activity 63 hA# 63 mTOR inhibitors 63 Xanafide 63 temsirolimus 63 CYT# 63 ELACYT 63 analgesic efficacy 63 Hsp# inhibition 63 azacytidine 63 Hematologic toxicity 63 anti angiogenic 63 XmAb# 63 BAL# [001] 63 tanespimycin 63 HuLuc# 63 S/GSK# 63 Eg5 63 cytotoxic agents 63 Panzem R NCD 63 pharmacokinetics PK 63 apremilast 63 bactericidal activity 63 potent inhibitor 63 HCV protease 63 posaconazole 63 targeting CD# 63 bendamustine 63 CBLC# 63 eniluracil 63 Seliciclib 63 tumor regressions 63 antiangiogenic 63 selective agonist 63 dose cohorts 63 Virulizin ® 63 indibulin 63 induce apoptosis 63 CD# antibody [001] 63 solid tumors 63 Erlotinib 63 Perifosine 63 Angiolix 63 CTAP# Capsules 63 Vidofludimus 63 lintuzumab 63 riociguat 63 imatinib therapy 63 TRAIL R2 63 vascular disrupting agent 63 mRCC 63 kinase inhibitor 63 MGd 63 Ceplene/IL-2 63 VEGF receptor 63 histone deacetylase inhibitor 63 chemotherapeutic drug 63 TRV# [001] 63 Targretin 63 TORISEL 63 YONDELIS 63 INGN 62 tumor necrosis 62 iniparib 62 immunoreactivity 62 afatinib 62 DAVANAT 62 microtubule targeting 62 TG# [003] 62 BZL# 62 intratumoral injection 62 bevacizumab Avastin ® 62 ritonavir boosted 62 oral JAK1 62 virologic response 62 FOLFIRI 62 immunomodulatory 62 gemcitabine 62 RGB # 62 rhIL 7 62 talabostat 62 intravesical 62 hematologic malignancies 62 sunitinib Sutent ® 62 Akt activation 62 Doxil ® 62 pharmacodynamics PD 62 trastuzumab emtansine T DM1 62 pharmacokinetic PK 62 anti proliferative 62 metaglidasen 62 resistant ovarian cancer 62 humanized anti 62 GAP #B# 62 etoposide 62 Amrubicin 62 IMA# 62 daunorubicin 62 Blinatumomab 62 Alocrest 62 kinase inhibition 62 neurotrophic 62 antiviral potency 62 receptor inhibitor 62 neurotoxicity 62 AEG# 62 FOLPI 62 interleukin IL -# 62 PI3K inhibitor 62 GFT# 62 sapacitabine 62 alkylating agent 62 huC# DM4 62 synthase TS 62 trastuzumab Herceptin ® 62 bleomycin 62 tumor xenograft models 62 NEUGENE 62 FOLFOX6 62 toxicities 62 Sym# 62 Etoposide 62 peripheral blood mononuclear 62 liposomal doxorubicin 62 CCR2 62 tolerability profiles 62 colon carcinoma 62 retapamulin 62 Hsp# inhibitor 62 MetMAb 62 chemopreventive 62 multi kinase inhibitor 62 rituximab 62 voreloxin 62 glucose lowering 62 CCR9 62 Interferon alpha 62 highly immunogenic 62 VEGF receptors 62 WT1 62 OncoVEX GM CSF 62 PEGylated interferon beta 1a 62 Archexin 62 Serdaxin 62 dosage regimens 62 amrubicin 62 HDAC inhibitor 62 Omacetaxine 62 PSN# [002] 62 preclinical studies 62 HuMax CD# 62 binding affinity 62 Trastuzumab 62 immunological responses 62 MET amplification 62 selective inhibitor 62 Debio 62 tipranavir 62 trabectedin 62 FGFR 62 Pralatrexate 62 hematological cancers 62 trastuzumab Herceptin R 62 JAK inhibitors 61 docetaxel Taxotere 61 anticancer agent 61 vorinostat 61 chemoradiotherapy 61 evaluating tivozanib 61 dasatinib 61 MGCD# [002] 61 tumorigenicity 61 EGFR HER2 61 proteasome inhibitors 61 CTGF 61 Pharmacokinetic studies 61 TNF α 61 rNAPc2 61 tocilizumab 61 romidepsin 61 metastatic RCC 61 neratinib 61 glufosfamide 61 RDEA# 61 pharmacodynamics 61 HIF PHI 61 docetaxel Taxotere R 61 novel histone deacetylase 61 chemotherapeutic agent 61 zalutumumab 61 EOquin TM 61 bortezomib Velcade ® 61 gemcitabine Gemzar ® 61 monotherapy 61 perifosine 61 c MYC 61 reversible inhibitor 61 mu opioid receptor antagonist 61 delafloxacin 61 CIMZIA TM 61 DXL# 61 HER3 61 gefitinib 61 ovarian carcinoma 61 radiation sensitizer 61 IFN gamma 61 cetuximab 61 Tarvacin 61 Vicinium TM 61 immune stimulatory 61 NXL# 61 5 FU 61 myelosuppression 61 antiangiogenic agents 61 varespladib 61 sunitinib malate 61 elotuzumab 61 nonclinical studies 61 vitro studies 61 hENT1 61 sorafenib Nexavar ® 61 tumor xenografts 61 relapsed SCLC 61 anti EGFR antibody 61 potent inhibition 61 INCB# [003] 61 dose cytarabine 61 antiproliferative effects 61 ixabepilone 61 HDAC inhibition 61 PKC# 61 plasma pharmacokinetics 61 secretory phospholipase A2 sPLA2 61 immunomodulator 61 Phase 2a trial 61 pharmacokinetic interactions 61 Antitumor Activity 61 antithrombotic 61 imatinib Gleevec ® 61 intratumoral 61 MAGE A3 ASCI 61 immunogenicity 61 vascular disrupting agents 61 androgen independent 61 docetaxel Taxotere ® 61 CR# vcMMAE 61 mecamylamine 61 cilengitide 61 cardiac toxicity 61 systemic toxicity 61 sunitinib 61 LY# [003] 61 OHR/AVR# 61 panobinostat 61 CDK inhibitor 61 microglial activation 61 mTOR inhibitor 61 potent antiviral 61 N cadherin 61 pharmacodynamic profiles 61 JAK inhibitor 61 Phase Ib II 61 tyrosine kinase inhibitor 61 Aplidin R 61 receptor tyrosine kinase inhibitor 61 trastuzumab 61 leukemia AML 61 fulvestrant 61 immunomodulatory effects 61 chlorambucil 61 LHRH receptor 61 pathophysiological effects 61 virologic responses 61 Pemetrexed 61 Epratuzumab 61 dexpramipexole 61 HIF PH inhibitors 61 estramustine 61 ORMD 60 AQ4N 60 ara C 60 Ceflatonin 60 Pharmacokinetics PK 60 TREANDA 60 multiple myeloma MM 60 neurologic progression 60 Aclidinium 60 antibody responses 60 forodesine 60 veltuzumab 60 gemcitabine cisplatin 60 vandetanib 60 oblimersen 60 dose escalation 60 thymalfasin 60 HSP# inhibitor 60 histologies 60 immunomodulation 60 immunogenic 60 lenalidomide dexamethasone 60 TG# [001] 60 GM CSF 60 docetaxel 60 HRPC 60 selective modulator 60 gemcitabine chemotherapy 60 goserelin 60 Aflibercept 60 phase IIb clinical 60 bevacizumab 60 PEG Interferon lambda 60 radezolid 60 galiximab 60 survivin 60 epithelial tumors 60 platinum refractory 60 platelet inhibition 60 Cloretazine R VNP#M 60 paclitaxel Taxol ® 60 DLTs 60 EGF receptor 60 oral Xeloda 60 solithromycin 60 hematologic toxicity 60 Bendavia 60 EndoTAG TM -1 60 mg/m2 dose 60 metastatic castration resistant 60 relapsed ovarian cancer 60 PRTX 60 tipifarnib 60 EGFR inhibitors 60 standard chemotherapy regimen 60 mg kg dose 60 bone metastasis 60 xenografts 60 Azixa 60 Fludarabine 60 anti fibrotic 60 transgene expression 60 protein kinase inhibitor 60 ALB # 60 indolent NHL 60 zanolimumab 60 recurrent NSCLC 60 sodium glucose cotransporter 60 anti amnesic 60 PTP 1B 60 Ophena TM 60 interferon beta 60 murine 60 DepoVax 60 KRAS status 60 anti angiogenic drugs 60 sorafenib 60 mycophenolate mofetil 60 interferon IFN 60 MabCampath 60 ISF# 60 orally administered inhibitor 60 CYT# potent vascular disrupting 60 PS# [001] 60 farletuzumab 60 XL# inhibits 60 Phase 1b 60 RoACTEMRA 60 melphalan prednisone 60 cytotoxic effects 60 chronic lymphocytic leukemia CLL 60 eculizumab 60 alpha folate receptor 60 immune modulating 60 KSP inhibitors 60 peptide antigens 60 GW# [003] 60 administered subcutaneously 60 chemotherapeutics 60 pharmacokinetics 60 low dose cytarabine 60 preclinical xenograft models 60 Pegasys ® 60 HGS ETR1 mapatumumab 60 EGFR TKI 60 vascular disrupting 60 antisense inhibition 60 Irinotecan 60 TriRima 60 intracellular uptake 60 humoral immune responses 60 proteasome inhibitor 60 TNFalpha 60 oral ridaforolimus 60 proteasome inhibitor bortezomib 60 histone deacetylase HDAC inhibitor 60 statistically significant efficacy 60 paclitaxel poliglumex 60 ZD# [001] 60 mitomycin 60 PCK# 60 teduglutide 60 IFN alpha 60 DOXIL 60 Hsp# inhibitors 60 taxanes 60 Dasatinib 60 HepG2 cells 60 polymerase inhibitor 60 EGFRvIII 60 IRX 2 60 IFN beta 60 Toxicities 60 Denufosol 60 VEGF inhibitors 60 ruxolitinib 60 human tumor xenografts 60 eltrombopag 60 velafermin 60 AKT inhibitor 60 Kinoid 60 radiochemotherapy 60 microRNA miR 60 dasatinib Sprycel ® 60 trabedersen 60 SCCHN 60 locoregional disease 60 Gleevec resistant 60 AT1R 60 delta isoform 60 PI3K/mTOR 60 TRIOLEX 60 remyelination 60 antibody MT# 60 Voreloxin 60 IGF 1R 60 Amphinex ® 59 AEGR 59 humanized monoclonal antibody 59 potent antiproliferative 59 potency selectivity 59 relapsed MM 59 dasatinib Sprycel 59 Dapagliflozin 59 CD# monoclonal antibody 59 mucosal healing 59 immunomodulating 59 insulin sensitizing 59 mitogenic 59 5 fluorouracil 59 HQK 59 carboplatin 59 chemopreventive agent 59 Taxotere ® 59 mGluR2 NAM 59 novel VDA molecule 59 iSONEP 59 CD# expressing 59 intravascular hemolysis 59 bronchodilation 59 taxane resistant 59 antiproliferative 59 noninferiority 59 crizotinib PF # 59 EGFR tyrosine kinase inhibitors 59 Omacetaxine mepesuccinate 59 Darinaparsin 59 CGEN # 59 idarubicin 59 immunohistochemical staining 59 HER2/neu 59 durable remissions 59 picoplatin 59 topotecan 59 RG# [001] 59 orthotopic 59 investigational monoclonal antibody 59 Valortim ® 59 IL #E 59 glucagon receptor 59 PI3K Akt 59 nanomolar 59 Neulasta ® 59 hypercalcemia 59 5FU 59 cariprazine 59 mRNA expression 59 SERMs 59 imatinib resistant 59 DFMO 59 tolerability pharmacokinetics 59 immunostimulatory 59 cyclophosphamide Cytoxan 59 masitinib 59 mTOR inhibition 59 AAG geldanamycin analog 59 ANAVEX #-# [001] 59 pharmacokinetic equivalence 59 Factor VIIa 59 novel peptide 59 pain palliation 59 antitumor responses 59 renal toxicity 59 cisplatin 59 CoFactor 59 Zybrestat 59 VNP#M 59 NF kappaB activation 59 dose escalation trial 59 HDACi 59 ZACTIMA 59 cetuximab Erbitux R 59 bortezomib Velcade 59 R#/MEM # 59 Valortim R 59 AEZS 59 ispinesib administered 59 oral antiviral 59 anticancer therapies 59 Tolerability 59 dacetuzumab 59 IGF 1R inhibitor 59 cannabinor 59 Onconase 59 PDE4 inhibitor 59 p# biomarkers 59 gefitinib Iressa 59 PC# cells 59 ZOLINZA 59 myeloproliferative diseases 59 TNFα 59 PLX# 59 VELCADE melphalan 59 PI3K/Akt pathway inhibitor 59 PEGylated Fab fragment 59 KRN# 59 rBChE 59 ofatumumab 59 Cytoxan 59 olaparib 59 Immunohistochemical analysis 59 immunostimulatory effects 59 immunostaining 59 Chemophase 59 Phase Ib study 59 pharmacokinetic characteristics 59 bevacizumab Avastin 59 TRAIL induced apoptosis 59 randomized Phase III 59 factor Xa inhibitor 59 mGluR5 NAM 59 Diffuse Large B 59 ProSavin 59 Amplimexon 59 Cloretazine ® 59 topoisomerase II inhibitor 59 EZN 59 amifostine 59 RLY# 59 parathyroid hormone PTH 59 Cloretazine 59 dosing regimens 59 K ras mutations 59 LHRH antagonists 59 ISIS # 59 paclitaxel Taxol 59 ARIKACE 59 plasma uric acid 59 mutational status 59 MUC1 59 thalidomide Thalomid 59 paclitaxel cisplatin 59 visilizumab 59 maximally tolerated dose 59 MAGE A3 59 custirsen 59 INCB# [002] 59 ADP receptor antagonist 59 coadministration 59 potent anticancer 59 pharmacokinetic PK study 59 fluvastatin 59 rFIXFc 59 tubulin inhibitor 59 Taxotere chemotherapy 59 Telintra 59 pharmacodynamic markers 59 phase Ib 59 cediranib 59 dose cohort 59 Hsp# Inhibitor 59 Zoraxel 59 Exherin TM 59 PEGylated anti 59 JAK2 inhibitors 59 neoadjuvant chemotherapy 59 trodusquemine 59 IGFBP 3 59 downregulation 59 atacicept 59 pharmacokinetic 59 Natalizumab 59 antiangiogenic therapy 59 ascending dose 59 pharmacokinetic parameters 59 Gefitinib 59 CTLA 4 59 antifibrotic 59 Golimumab 59 virologic 59 tumor vasculature 59 CRLX# 59 darinaparsin 59 MAPK pathway 59 effector functions 59 sipuleucel T 59 taxane refractory 59 alpha#beta# integrin 59 Gemcitabine 59 ToGA 59 dacarbazine 59 relapsed multiple myeloma 59 MEK inhibitors 59 plus dexamethasone 59 GPNMB 59 bortezomib Velcade R 59 NS4A 59 NOD SCID mice 59 partial agonist 59 BiTE ® 59 IL 1β 59 bosentan 59 hepatic fibrosis 59 anti angiogenic agent 59 immunomodulatory therapy 59 nucleoside analog 59 rHuPH# 59 syngeneic 59 immune reconstitution 59 factor G CSF 59 ProLindac 59 leukemic cell 59 5 Fluorouracil 59 anticancer 59 JAK2 inhibitor 59 LymphoStat B 59 ISTODAX 59 irinotecan chemotherapy 59 MDV# 59 DACH platinum 59 antiapoptotic 59 cytotoxic chemotherapy 59 cardioprotective effects 58 unresectable 58 cyclin dependent kinases CDKs 58 bexarotene 58 T DM1 58 receptor antagonists 58 orally dosed 58 VAPRISOL 58 ARRY 58 oxidative stress inducer 58 cardiotoxicity 58 cisplatin gemcitabine 58 MAP# 58 lung metastases 58 HIV RNA 58 TRAIL receptors 58 adalimumab 58 lung fibrosis 58 BiTE antibody 58 Phase 1b trial 58 CEQ# 58 cisplatin resistant 58 prostate cancer AIPC 58 xenograft tumors 58 temozolomide 58 selective kinase inhibitor 58 HCV protease inhibitors 58 ACZ# 58 superficial bladder cancer 58 JAK1 58 MEK inhibitor 58 vinorelbine 58 FOLFOX chemotherapy 58 PDGFR 58 IL 1ß 58 ZYBRESTAT 58 pazopanib 58 JVRS 58 intravesical instillation 58 VIDAZA 58 EGFR expression 58 p# mitogen activated 58 deforolimus 58 Phase Ib clinical 58 tumor shrinkage 58 Panzem 58 Proxinium TM 58 neutralizing antibody 58 BMS# 58 IAP inhibitor 58 Vitaxin 58 BRIM2 58 satraplatin Phase 58 cell lymphoma CTCL 58 HuMax CD4 58 inhibitory effect 58 fibrotic disease 58 Quinamed 58 fosamprenavir 58 clinical trials Multikine 58 HspE7 58 vWF 58 otelixizumab 58 c MET 58 Cotara 58 SAR# [004] 58 ONCONASE 58 fluoropyrimidine 58 TRO# 58 neointimal hyperplasia 58 Lenocta 58 Tarceva erlotinib 58 cisplatin vinorelbine 58 efficacy tolerability 58 EndoTAGTM 1 58 Triolex 58 irreversible inhibitor 58 cutaneous T cell 58 Janus kinase 58 oral FTY# 58 lytic 58 metastatic malignant 58 vinca alkaloid 58 octreotide 58 Taxol paclitaxel 58 investigational compound 58 pancreatic adenocarcinoma 58 #I TM# 58 PI3K delta 58 Cisplatin 58 FGFR2 58 CANCIDAS 58 ERK1 2 58 iNOS 58 prostate cancer mCRPC 58 EORTC 58 nilotinib 58 deferiprone 58 factor TNF 58 placebo controlled clinical 58 NP2 Enkephalin 58 PROSTVAC TM 58 PEGPH# 58 hormone refractory prostate cancer 58 tesmilifene 58 prucalopride 58 neuroprotective effects 58 ascending doses 58 Pharmacokinetic PK 58 oral diclofenac 58 Linaclotide 58 PROCHYMAL 58 Vidaza azacitidine 58 Posiphen 58 subcutaneous formulation 58 Elacytarabine 58 p# inhibitor 58 antitumoral 58 Panzem R 58 novel anticancer 58 motesanib 58 Cloretazine R 58 phase IIa clinical 58 Axitinib 58 evaluable patients 58 flavopiridol 58 myelodysplastic syndromes MDS 58 inhibitor RG# 58 CXB# 58 D aspartate NMDA receptor 58 polymerase inhibitors 58 Nilotinib 58 chloride secretion 58 interferon γ 58 molecularly targeted 58 aflibercept 58 FTY# 58 NS#/#A protease 58 belinostat 58 #D#C# 58 refractory NSCLC 58 Notch1 58 mesothelin 58 IgG1 antibody 58 viral suppression 58 cytostatic 58 talactoferrin 58 PROMACTA 58 TACI Ig 58 bevacizumab Avastin R 58 TELINTRA 58 LUX Lung 58 Torisel 58 TGF beta1 58 potent anti angiogenic 58 SSc 58 Epidermal Growth Factor Receptor 58 cisplatin chemotherapy 58 NY ESO 58 transfected 58 selective antagonist 58 clusterin 58 metastatic lesions 58 anticancer agents 58 vivo 58 metastatic CRC 58 alpha 2a 58 lymphoma CTCL 58 dosing cohort 58 overexpression 58 carfilzomib 58 TLR7 58 TNFa 58 HER2 overexpression 58 sorafenib tablets 58 vemurafenib 58 TELCYTA 58 Aliskiren 58 murine model 58 EGFR 58 pemetrexed 58 cardiovascular morbidity 58 platelet reactivity 58 oral deforolimus 58 optimal dosing 58 compound AEZS 58 Taxotere R 58 EGFR mutations 58 #mg dose [001] 58 retaspimycin 58 Annamycin 58 lapatinib Tykerb 58 chemotherapy docetaxel 58 HER2 receptor 58 PRX#

Back to home page